Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept combined with dexamethasone intravitreal implant for macular edema secondary to central retinal vein occlusion
ChiCTR2000040087Phase 3Recruiting
- Sponsor
- Department of Ophthalmology, Central Theater Command General Hospital
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of conbercept and dexamethasone in central retinal vein occlusion (CRVO) (2 arms), sponsored by Department of Ophthalmology, Central Theater Command General Hospital. Primary endpoints: Number of injections, Best corrected visual acuity and 1 more. Started Jun 2020; status: recruiting.
02
Drugs
conberceptdexamethasone
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on ChiCTR2000040087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040087.